TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

Clinical Trial ID NCT00694629

PubWeight™ 16.65^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00694629

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Advances in the development of new tuberculosis drugs and treatment regimens.	Nat Rev Drug Discov	2013	3.50
2	Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.	Am J Respir Crit Care Med	2015	1.86
3	Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.	Antimicrob Agents Chemother	2012	1.63
4	Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.	J Infect Dis	2012	1.53
5	Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.	PLoS One	2013	1.24
6	Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.	Clin Pharmacol Ther	2012	1.23
7	Current development and future prospects in chemotherapy of tuberculosis.	Respirology	2010	1.12
8	TB and HIV Therapeutics: Pharmacology Research Priorities.	AIDS Res Treat	2012	0.94
9	Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.	Tuberculosis (Edinb)	2014	0.90
10	Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.	Tuberculosis (Edinb)	2015	0.83
11	Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response.	Tuberculosis (Edinb)	2012	0.79
12	New drugs and regimens for treatment of TB.	Expert Rev Anti Infect Ther	2010	0.77
13	Activism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovations.	Public Health Action	2014	0.75